Towards that end, we treated orthotopic PyMT or KPC tumor-bearing mice with antibodies against VEGF receptor-2 (VEGFR2) at 40 mg/kg or 10 mg/kg, two doses previously shown to deplete or normalize tumor vasculature respectively42. Here, KDR is linked to neoplasm.